Q-linea postpones start of the clinical trials
Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), today announced that the clinical trials, in the United States and Europe, for the company's first product ASTar® are expected to begin in the second half of 2020. This is a postponement as the trials previously were expected to start in the first quarter of 2020. The reason is partly that Q-linea during the evaluation of ASTar during the autumn realized that the reliability of a third-party component needs to be improved. In addition, Q-linea have conducted several interviews with physicians in Europe and the US during the summer. With the new